| Identification | Back Directory | [Name]
1,5,9-Triazacyclododecane, 3-methylene-1,5-bis[(4-methylphenyl)sulfonyl]-9-(phenylmethyl)- | [CAS]
182316-44-5 | [Synonyms]
Cyclotriazadisulfonamide
1,5,9-Triazacyclododecane, 3-methylene-1,5-bis[(4-methylphenyl)sulfonyl]-9-(phenylmethyl)- | [Molecular Formula]
C31H39N3O4S2 | [MOL File]
182316-44-5.mol | [Molecular Weight]
581.79 |
| Chemical Properties | Back Directory | [Melting point ]
160-164 °C(Solv: ethyl acetate (141-78-6)) | [Boiling point ]
706.2±70.0 °C(Predicted) | [density ]
1.28±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [form ]
Solid | [pka]
7.98±0.20(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Cyclotriazadisulfonamide (CADA) is a specific CD4-targeted HIV entry inhibitors. Cyclotriazadisulfonamide (CADA) inhibits the co-translational translocation of human CD4 (huCD4) into the ER lumen in a signal peptide (SP)-dependent way. Cyclotriazadisulfonamide is also a Sec61 translocon inhibitor[1][2][3]. | [IC 50]
HIV-1 | [storage]
Store at -20°C | [References]
[1] Kurt Vermeire, et al. CADA, a potential anti-HIV microbicide that specifically targets the cellular CD4 receptor. Curr HIV Res. 2008 May;6(3):246-56. DOI:10.2174/157016208784324958
[2] Victor Van Puyenbroeck, et al. Preprotein signature for full susceptibility to the co-translational translocation inhibitor cyclotriazadisulfonamide. Traffic. 2020 Feb;21(2):250-264. DOI:10.1111/tra.12713
[3] Pauwels E, et al. Inhibitors of the Sec61 Complex and Novel High Throughput Screening Strategies to Target the Protein Translocation Pathway. Int J Mol Sci. 2021 Nov 5;22(21):12007. DOI:10.3390/ijms222112007 |
|
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 13348960310 |
| Website: |
https://www.weikeqi-biotech.com/ |
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|